APA (7th ed.) Citation

Abdel-Razeq, H., Alsayed, A., Dawoud, E., Al Kharusi, S., Hammad Tirmazy, S., Ahmed, E., . . . Soliman, W. (2025). 533P Real-world evidence on safety and effectiveness study of ribociclib plus hormonal therapy in HR+/HER2– advanced breast cancer in the middle east: Interim results from the REALEESA study. Annals of Oncology, 36, S426. https://doi.org/10.1016/j.annonc.2025.08.956

Chicago Style (17th ed.) Citation

Abdel-Razeq, H., A. Alsayed, E. Dawoud, S.S Al Kharusi, S. Hammad Tirmazy, E. Ahmed, L. Alhawari, M. Kasseb, and W. Soliman. "533P Real-world Evidence on Safety and Effectiveness Study of Ribociclib Plus Hormonal Therapy in HR+/HER2– Advanced Breast Cancer in the Middle East: Interim Results from the REALEESA Study." Annals of Oncology 36 (2025): S426. https://doi.org/10.1016/j.annonc.2025.08.956.

MLA (9th ed.) Citation

Abdel-Razeq, H., et al. "533P Real-world Evidence on Safety and Effectiveness Study of Ribociclib Plus Hormonal Therapy in HR+/HER2– Advanced Breast Cancer in the Middle East: Interim Results from the REALEESA Study." Annals of Oncology, vol. 36, 2025, p. S426, https://doi.org/10.1016/j.annonc.2025.08.956.